A dose-response relationship — more of a thing producing more of an effect — is one of the stronger signals available in nutrition science, because it's much harder to explain away than a single positive trial. For omega-3 and cognitive function, a 2025 meta-analysis went looking for exactly that.
The evidence base
A systematic review and dose-response meta-analysis pooled 58 randomized controlled trials, with doses ranging from 230mg to nearly 5,000mg/day and trial lengths from 4 to 160 weeks.1
What the dose-response curve showed
For every additional 2,000mg/day of omega-3 intake, researchers measured improvements across several cognitive domains: memory, processing speed, language, global cognitive ability, and visuospatial function.1 That's a genuine dose-response finding, not a single before-and-after comparison — the effect size moved in the same direction as the dose across dozens of independently run trials, which is exactly the pattern that makes a nutrition claim harder to dismiss as noise.
Why omega-3 is thought to affect cognition at all
A dose-response curve tells you a pattern exists. It doesn't by itself explain why. The mechanistic story for omega-3 and the brain runs through two related but distinct fatty acids — EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — and they are not interchangeable.
DHA is structurally built into neuronal membranes. It's one of the most abundant fatty acids in the phospholipid bilayer of brain cell membranes, particularly at synapses, where it's thought to increase membrane fluidity — the physical flexibility that lets membrane-embedded receptors and ion channels function properly, and that supports the vesicle trafficking involved in forming new synaptic connections.2 Low brain DHA status has been associated with reduced synaptic density and altered neurotransmission in animal models, which is part of why DHA in particular is framed as a structural, rather than purely signaling, nutrient for the nervous system.2
EPA, by contrast, is metabolized into a different set of signaling molecules — eicosanoids and specialized pro-resolving mediators that shape the inflammatory response.3 Chronic low-grade neuroinflammation is one of the more consistent findings in cognitive aging research, and EPA's anti-inflammatory signaling is the proposed route by which it could support cognitive function even though it makes up a smaller share of brain membrane fatty acids than DHA does.
Put simply: DHA is more about the hardware, EPA is more about calming the environment the hardware sits in. A meta-analysis measuring "omega-3" as one pooled variable, as the 2025 dose-response study does, is necessarily blending both mechanisms together.
DHA is built into the membrane. EPA changes the signaling environment around it. "Omega-3" is really two ingredients wearing one name.
Does the EPA:DHA ratio matter for cognition specifically?
This is a genuinely well-studied distinction in omega-3 research generally, and the honest answer for cognition is: it's not settled, and the two outcome areas where omega-3 is best studied — heart health and brain health — don't point the same direction. Large cardiovascular trials have generally favored EPA-dominant or EPA-only formulations. Cognitive research is messier and, if anything, leans the other way at the individual-trial level.
The clearest head-to-head test came from a 2021 randomized controlled trial in the American Journal of Clinical Nutrition, which gave 310 healthy adults aged 25–49 either an EPA-rich oil (900mg EPA + 360mg DHA/day), a DHA-rich oil (900mg DHA + 270mg EPA/day), or a placebo for 26 weeks. The EPA-rich formulation improved global cognitive function — both accuracy and processing speed — while the DHA-rich formulation did not reach the same result in that trial.4 That's one well-designed trial in healthy young adults, and it cuts against the common assumption that DHA is automatically the "brain" fatty acid and EPA is the "heart" one.
The 2025 dose-response meta-analysis doesn't resolve this either way — it pooled trials using DHA alone, EPA alone, and combined formulations together under a single "omega-3" dose variable, so it can't tell us whether a given ratio outperforms another.1 The fair summary is that both fatty acids show real, independently plausible mechanisms and some independently positive trials, and the field hasn't produced a confident answer on optimal ratio for cognitive outcomes specifically. We're not going to claim otherwise.
Who the effect looks strongest for
Dose matters, but so does who's taking it. Two trials outside the 2025 meta-analysis illustrate the range. In the MIDAS trial, 485 adults aged 55 and older with age-related cognitive decline and subjective memory complaints took 900mg/day of algal DHA for 24 weeks and showed measurable improvement in memory and learning compared with placebo.5 At the other end, AREDS2 — a five-year trial in roughly 4,000 older adults (average age 72) with early or intermediate age-related macular degeneration — tested a lower combined dose, 350mg DHA plus 650mg EPA daily, and found no slowing of cognitive decline at all.6
Those two results aren't necessarily a contradiction. The MIDAS population had documented age-related cognitive decline going in, the dose was substantially higher on the DHA side, and the outcome measure was memory improvement rather than decline prevention. AREDS2 enrolled people without diagnosed cognitive impairment, dosed lower, and asked a harder question — can omega-3 prevent decline that hasn't started yet — over a much longer timeframe. The 2025 meta-analysis itself notes that its own pooled trials varied by participant age and baseline health status as a built-in part of the analysis, which is consistent with the idea that starting point matters for how much room there is to see improvement.1 None of this supports a claim that omega-3 treats or prevents dementia — it doesn't, and no trial here says it does — but it is a reason the modest, population-wide effect in the big meta-analysis coexists with a much clearer signal in specific groups with lower baseline cognitive status.
The caveats that matter
Certainty of evidence was graded low-to-moderate — real signal, not proof at the highest evidentiary bar. And two domains, memory and global cognition, didn't respond in a straight line: they improved, then tailed off at very high doses, meaning "more is better" doesn't hold indefinitely for every outcome measured.
What the researchers themselves concluded
The authors' own language was that omega-3 "may lead to a modest improvement in cognitive function" — with an explicit call for longer, better-designed trials. That's a considered, moderate conclusion, and it's the one we're working from.
What a realistic dose actually looks like
The 2,000mg/day increment used in the dose-response finding is a research unit, not a serving size — it's the step size researchers used to model the curve, not a single trial's dose. Most commercial fish oil capsules deliver far less than that per serving; a standard over-the-counter softgel is commonly in the 250–500mg EPA+DHA combined range, which means someone taking one capsule a day is often getting a quarter or less of the dose increment the meta-analysis measured. Closing that gap generally means either a higher-potency formulation or multiple capsules a day, and it's worth checking the actual EPA+DHA figure on the supplement facts panel rather than assuming "fish oil" means the same dose across brands. For the exact EPA and DHA breakdown in Proco's own Omega-3 formulation, the product page has the full label — we're not going to restate a number here that isn't in front of you on the panel itself.
What we take from this
Omega-3 has the deepest evidence base of the ingredients we carry for cognitive health, and this dose-response data is part of why. We dose to the range the trials studied, and we describe the effect the way the meta-analysis itself does: a modest, real improvement — not a cognitive enhancer with no ceiling.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease, including cognitive decline or dementia. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Scientific Reports (Nature) (2025). Systematic review and dose-response meta-analysis of omega-3 supplementation on cognitive function. nature.com/articles/s41598-025-16129-8
- Bazinet RP, Layé S (2014). Polyunsaturated fatty acids and their metabolites in brain function and disease. Nature Reviews Neuroscience, 15(12), 771–785. nature.com/articles/nrn3820
- Calder PC (2010). Omega-3 fatty acids and inflammatory processes. Nutrients, 2(3), 355–374. mdpi.com/2072-6643/2/3/355
- Patan MJ, Kennedy DO, Husberg C, et al. (2021). Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials. American Journal of Clinical Nutrition, 114(3), 914–924. pmc.ncbi.nlm.nih.gov/articles/PMC8408864
- Yurko-Mauro K, McCarthy D, Rom D, et al. (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's & Dementia, 6(6), 456–464. alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2010.01.013
- Chew EY, et al., Age-Related Eye Disease Study 2 Research Group (2015). Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA, 314(8), 791–801. nei.nih.gov — NIH study summary
Related reading
- What the Research Actually Says About Nutrition and Attention
- Burnout and Cognitive Failure: What the Research Shows
Want to know what's actually in what you take? Join the list — no spam, just it straight.